Alyssa C. Flint

Alyssa C. Flint

Auto-generated profile, based on publicly available information

Alyssa C. Flint

Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
AFAlyssa C. Flint
Alyssa C. Flint
DMDana K. Mitchell
Dana K. Mitchell
SASteven P. Angus
Steven P. Angus
ASAbbi E. Smith
Abbi E. Smith
WBWaylan Bessler
Waylan Bessler
SRSteven Rhodes
Steven Rhodes
Purpose: Plexiform neurofibromas (PNF) are peripheral nerve sheath tumors that cause significant morbidity in persons with neurofibromatosis type 1 (NF1), yet treatment options remain limited. To identify novel therapeutic targets for PNF, we applied an integrated multi-omic approach to quantitatively profile kinome enrichment in a mouse model that has predicted therapeutic responses in clinical trials for NF1-associated PNF with high fidelity. Experimental Design: Utilizing RNA sequencing combined with chemical proteomic profiling of the functionally enriched kinome using multiplexed inhibitor beads coupled with mass spectrometry, we identified molecular signatures predictive of response to CDK4/6 and RAS/MAPK pathway inhibition in PNF. Informed by these results, we evaluated the efficacy of the CDK4/6 inhibitor, abemaciclib, and the ERK1/2 inhibitor, LY3214996, alone and in combination in reducing PNF tumor burden in Nf1flox/flox;PostnCre mice. Results: Converging signatures of CDK4/6 and RAS/MAPK pathway activation were identified within the transcriptome and kinome that were conserved in both murine and human PNF. We observed robust additivity of the CDK4/6 inhibitor, abemaciclib, in combination with the ERK1/2 inhibitor, LY3214996, in murine and human NF1(Nf1) mutant Schwann cells. Consistent with these findings, the combination of abemaciclib (CDK4/6i) and LY3214996 (ERK1/2i) synergized to suppress molecular signatures of MAPK activation and exhibited enhanced antitumor activity in Nf1flox/flox;PostnCre mice in vivo. Conclusions: These findings provide rationale for the clinical translation of CDK4/6 inhibitors alone and in combination with therapies targeting the RAS/MAPK pathway for the treatment of PNF and other peripheral nerve sheath tumors in persons with NF1.

30 January 2026 in Science Advances
Verified
Journal Article
Open access
DMDana K. Mitchell
Dana K. Mitchell
KBKylee Brewster
Kylee Brewster
LJLi Jiang
Li Jiang
HMHenry Mang
Henry Mang
WBWaylan K. Bessler
Waylan K. Bessler
DCD. Wade Clapp
D. Wade Clapp
NF2 (neurofibromatosis type 2)–related schwannomatosis (NF2-SWN) is a cancer predisposition syndrome characterized by the development of bilateral vestibular (VS) and spinal schwannomas. While benign, these tumors can cause substantial morbidity, and effective pharmacological treatments remain limited. Here, we demonstrate that genetic ablation of focal adhesion kinase ( Fak/Ptk2 ) impairs tumor formation and preserves hearing in a murine model of NF2. Mechanistically, we show that Fak deletion decreases macrophage infiltration, attenuates nucleotide-binding oligomerization domain–containing protein 2–, leucine rich repeats (LRR)- and pyrin domain–containing protein 3 inflammasome activation, and suppresses the hepatocyte growth factor–MET axis. Pharmacological inhibition of FAK with single agent VS-4718 did not significantly reduce macroscopic tumor volume; however, its use in combination with the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib resulted in both a significant reduction in tumor volume and the preservation of dorsal root ganglion architecture. Our findings establish a critical role for FAK in schwannoma development and provide rationale for evaluation of combination FAK plus MEK inhibition in future clinical trials for NF2-associated SWN.



25 November 2025
Verified
Other
Open access
AFAlyssa C. Flint
Alyssa C. Flint
DMDana K. Mitchell
Dana K. Mitchell
SASteven P. Angus
Steven P. Angus
ASAbbi E. Smith
Abbi E. Smith
WBWaylan Bessler
Waylan Bessler
SRSteven Rhodes
Steven Rhodes
Etv4, Dusp6, Phlda1, and Dusp4 mRNA expression

25 November 2025
Verified
Other
Open access
AFAlyssa C. Flint
Alyssa C. Flint
DMDana K. Mitchell
Dana K. Mitchell
SASteven P. Angus
Steven P. Angus
ASAbbi E. Smith
Abbi E. Smith
WBWaylan Bessler
Waylan Bessler
SRSteven Rhodes
Steven Rhodes
Pharmacokinetic properties of LY3214996 and abemaciclib